Time to treatment discontinuation
T790M-positive, TTD
Of 1350 enrolled patients, 349 patients (25.9%) transitioned to the commercial drug at the time of national reimbursement; the remaining 1001 patients (74.1%) discontinued the treatment, with a median TTD of 13.9 months (95% CI 13.1–15.2). The median TTD in patients with T790M-positive status by tissue testing and plasma testing was 16.1 months (95% CI 15.2–16.8) and 11.6 months (95% CI 11.0–12.6), respectively (Fig. Kaplan-Meir plot for TTD in 